Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14134418 | 0.84 | ADORA3 (0.32) | ALOX5 | |
| SCHEMBL14878224 | 0.75 | — | — | |
| SCHEMBL14286794 | 0.75 | ALOX5 (0.37) | CYP2C19ALOX5 | |
| SCHEMBL14733766 | 0.71 | — | — | |
| SCHEMBL16576817 | 0.69 | KDM4E (0.30) | KDM4E | |
| SCHEMBL31155758 | 0.69 | KDM4E (0.40) | KDM4ECYP1A2GAACYP2C19 | |
| SCHEMBL12558040 | 0.69 | KDM4E (0.40) | KDM4ECYP1A2GAACYP2C19 | |
| SCHEMBL12440785 | 0.69 | — | — | |
| SCHEMBL15423096 | 0.67 | ESR2 (0.38) | KDM4ECYP1A2GAACYP2C19 | |
| SCHEMBL16546136 | 0.67 | NQO2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466311-B2 | Neuroprotective compositions and methods | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120296112-A1 | Neuroprotective Compositions and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | disclosed |
| US-8022246-B2 | Neuroprotective compositions and methods | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-09-20 | — | — | US | disclosed |
| US-7947733-B2 | Phosphorylated pyrone analogs and methods | LIMERICK BIOPHARMA (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100204089-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100144612-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20090069273-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090042980-A1 | Neuroprotective compositions and methods | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042980-A1 | Neuroprotective compositions and methods | KEAP1, NFE2L2, NQO1 | KDM4E 3648/4885CYP1A2 3481/4885GAA 3689/4885 |
| US-20090069273-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | KDM4E 1623/4885CYP1A2 832/4885GAA 2675/4885 |
| US-20120296112-A1 | Neuroprotective Compositions and Methods | KEAP1, NFE2L2, NQO1 | KDM4E 3648/4885CYP1A2 3481/4885GAA 3689/4885 |
| US-20100144612-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | KDM4E 1623/4885CYP1A2 832/4885GAA 2675/4885 |
| US-20100204089-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | KDM4E 1623/4885CYP1A2 832/4885GAA 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.